{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:40:18Z","timestamp":1788928818215,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00115-024-01725-2","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T11:01:54Z","timestamp":1726830114000},"page":"920-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Periphere neuroimmunologische Erkrankungen\u00a0\u2013 neuropathologische Einsichten und klinische Perspektiven","Peripheral neuroimmunological diseases---Neuropathological insights and clinical perspectives"],"prefix":"10.1007","volume":"95","author":[{"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Preu\u00dfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Ruffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"1725_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.nmd.2020.02.003","volume":"30","author":"J Day","year":"2020","unstructured":"Day\u00a0J, Otto\u00a0S, Cash\u00a0K, Limaye\u00a0V (2020) Clinical and histological features of immune-mediated necrotising myopathy: A\u00a0multi-centre South Australian cohort study. Neuromuscul Disord 30:186\u2013199. https:\/\/doi.org\/10.1016\/j.nmd.2020.02.003","journal-title":"Neuromuscul Disord"},{"key":"1725_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo\u00a0T, Lilleker\u00a0JB, Thong\u00a0BYH et\u00a0al (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19:695\u2013712. https:\/\/doi.org\/10.1038\/s41584-023-01033-0","journal-title":"Nat Rev Rheumatol"},{"key":"1725_CR3","doi-asserted-by":"publisher","first-page":"E1193","DOI":"10.1212\/WNL.0000000000008128","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez\u00a0I, Casal-Dominguez\u00a0M, Derfoul\u00a0A et\u00a0al (2019) Identification of distinctive interferon gene signatures in different types of myositis. Neurology 93:E1193\u2013E1204. https:\/\/doi.org\/10.1212\/WNL.0000000000008128","journal-title":"Neurology"},{"key":"1725_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach\u00a0Y, Uzunhan\u00a0Y, Toquet\u00a0S et\u00a0al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 95:70\u201378. https:\/\/doi.org\/10.1212\/WNL.0000000000009727","journal-title":"Neurology"},{"key":"1725_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard-2023-223873","volume":"82","author":"I Pinal-Fernandez","year":"2023","unstructured":"Pinal-Fernandez\u00a0I, Milisenda\u00a0JC, Pak\u00a0K et\u00a0al (2023) Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis 82:1091\u20131097. https:\/\/doi.org\/10.1136\/ard-2023-223873","journal-title":"Ann Rheum Dis"},{"key":"1725_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/00015555-3091","volume":"99","author":"M Best","year":"2019","unstructured":"Best\u00a0M, Molinari\u00a0N, Chasset\u00a0F et\u00a0al (2019) Use of anti-transcriptional intermediary factor\u20111 gamma autoantibody in identifying adult dermatomyositis patients with cancer: A\u00a0systematic review and meta-analysis. Acta Derm Venereol 99:256\u2013262. https:\/\/doi.org\/10.2340\/00015555-3091","journal-title":"Acta Derm Venereol"},{"key":"1725_CR7","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/art.42474","volume":"75","author":"D Fiorentino","year":"2023","unstructured":"Fiorentino\u00a0D, Mecoli\u00a0CA, Igusa\u00a0T et\u00a0al (2023) Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1\u03b3-Positive Dermatomyositis. Arthritis Rheumatol 75:1238\u20131245. https:\/\/doi.org\/10.1002\/art.42474","journal-title":"Arthritis Rheumatol"},{"key":"1725_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","volume":"77","author":"I Nishino","year":"2020","unstructured":"Nishino\u00a0I, Inoue\u00a0M, Tanboon\u00a0J et\u00a0al (2020) Association of Dermatomyositis Sine Dermatitis with Anti-Nuclear Matrix Protein\u00a02 Autoantibodies. JAMA Neurol 77:872\u2013877. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0673","journal-title":"JAMA Neurol"},{"key":"1725_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"AGS Oldroyd","year":"2023","unstructured":"Oldroyd\u00a0AGS, Callen\u00a0JP, Chinoy\u00a0H et\u00a0al (2023) International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol 19:805\u2013817. https:\/\/doi.org\/10.1038\/s41584-023-01045-w","journal-title":"Nat Rev Rheumatol"},{"key":"1725_CR10","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","volume":"90","author":"Y Allenbach","year":"2018","unstructured":"Allenbach\u00a0Y, Arouche-Delaperche\u00a0L, Preusse\u00a0C et\u00a0al (2018) Necrosis in anti-SRP + and anti-HMGCR + myopathies. Neurology 90:e507\u2013e517. https:\/\/doi.org\/10.1212\/WNL.0000000000004923","journal-title":"Neurology"},{"key":"1725_CR11","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","volume":"5","author":"AL Mammen","year":"2023","unstructured":"Mammen\u00a0AL, Amato\u00a0AA, Dimachkie\u00a0MM et\u00a0al (2023) Zilucoplan in immune-mediated necrotising myopathy: a\u00a0phase\u00a02, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol 5:e67\u2013e76. https:\/\/doi.org\/10.1016\/S2665-9913(23)00003-6","journal-title":"Lancet Rheumatol"},{"key":"1725_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","volume":"144","author":"C Preu\u00dfe","year":"2022","unstructured":"Preu\u00dfe\u00a0C, Paesler\u00a0B, Nelke\u00a0C et\u00a0al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 144:353\u2013372. https:\/\/doi.org\/10.1007\/s00401-022-02438-z","journal-title":"Acta Neuropathol"},{"key":"1725_CR13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett\u00a0G, Mackensen\u00a0A, Mougiakakos\u00a0D (2023) CAR T\u2011cell therapy in autoimmune diseases. Lancet 402:2034\u20132044. https:\/\/doi.org\/10.1016\/S0140-6736(23)01126-1","journal-title":"Lancet"},{"key":"1725_CR14","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/brain\/awz207","volume":"142","author":"SA Greenberg","year":"2019","unstructured":"Greenberg\u00a0SA, Pinkus\u00a0JL, Kong\u00a0SW et\u00a0al (2019) Highly differentiated cytotoxic T\u00a0cells in inclusion body myositis. Brain 142:2590\u20132604. https:\/\/doi.org\/10.1093\/brain\/awz207","journal-title":"Brain"},{"key":"1725_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.abi9196","volume":"14","author":"KA Britson","year":"2022","unstructured":"Britson\u00a0KA, Ling\u00a0JP, Braunstein\u00a0KE et\u00a0al (2022) Loss of TDP-43 function and rimmed vacuoles persist after T\u00a0cell depletion in a\u00a0xenograft model of sporadic inclusion body myositis. Sci Transl Med 14:1\u201332. https:\/\/doi.org\/10.1126\/scitranslmed.abi9196","journal-title":"Sci Transl Med"},{"key":"1725_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","volume":"37","author":"JB Lilleker","year":"2024","unstructured":"Lilleker\u00a0JB, Naddaf\u00a0E, Saris\u00a0CGJ et\u00a0al (2024) 272nd ENMC international workshop: 10 Years of progress\u2014revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318\u00a0June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 37:36\u201351. https:\/\/doi.org\/10.1016\/j.nmd.2024.03.001","journal-title":"Neuromuscul Disord"},{"key":"1725_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem\u00a0JE, Bretagne\u00a0M, Abbar\u00a0B et\u00a0al (2023) Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov 13:1100\u20131115. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"key":"1725_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000200177","volume":"11","author":"C Nelke","year":"2024","unstructured":"Nelke\u00a0C, Pawlitzki\u00a0M, Kerkhoff\u00a0R et\u00a0al (2024) Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. Neurol Neuroimmunol Neuroinflammation 11:1\u20135. https:\/\/doi.org\/10.1212\/NXI.0000000000200177","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"1725_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","volume":"147","author":"C Nelke","year":"2024","unstructured":"Nelke\u00a0C, Schmid\u00a0S, Kleefeld\u00a0F et\u00a0al (2024) Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. Acta Neuropathol 147:15. https:\/\/doi.org\/10.1007\/s00401-023-02669-8","journal-title":"Acta Neuropathol"},{"key":"1725_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"1725_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00292-009-1156-x","volume":"31","author":"K Holl-Ulrich","year":"2010","unstructured":"Holl-Ulrich\u00a0K (2010) Histopathologie systemischer Vaskulitiden. Pathologe 31:67\u201376. https:\/\/doi.org\/10.1007\/s00292-009-1156-x","journal-title":"Pathologe"},{"key":"1725_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103093","author":"J Rohmer","year":"2023","unstructured":"Rohmer\u00a0J, Nguyen\u00a0Y, Trefond\u00a0L et\u00a0al (2023) Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients. J\u00a0Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2023.103093","journal-title":"J Autoimmun"},{"key":"1725_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","volume":"403","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler\u00a0A, Bajema\u00a0IM, Bruchfeld\u00a0A et\u00a0al (2024) Diagnosis and management of ANCA-associated vasculitis. Lancet 403:683\u2013698. https:\/\/doi.org\/10.1016\/S0140-6736(23)01736-1","journal-title":"Lancet"},{"key":"1725_CR24","doi-asserted-by":"publisher","first-page":"103391","DOI":"10.1016\/j.autrev.2023.103391","volume":"22","author":"P Mertz","year":"2023","unstructured":"Mertz\u00a0P, Wollenschlaeger\u00a0C, Chasset\u00a0F et\u00a0al (2023) Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev 22:103391. https:\/\/doi.org\/10.1016\/j.autrev.2023.103391","journal-title":"Autoimmun Rev"},{"key":"1725_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00393-019-0595-x","volume":"78","author":"M Krusche","year":"2019","unstructured":"Krusche\u00a0M, Ruffer\u00a0N, Kubacki\u00a0T et\u00a0al (2019) Muscular polyarteritis nodosa\u2014a case-based review. Z\u00a0Rheumatol 78:173\u2013179. https:\/\/doi.org\/10.1007\/s00393-019-0595-x","journal-title":"Z Rheumatol"},{"key":"1725_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00296-020-04652-y","volume":"40","author":"S Ushiyama","year":"2020","unstructured":"Ushiyama\u00a0S, Shimojima\u00a0Y, ichi\u00a0UK et\u00a0al (2020) Clinical characteristics of patients with myalgia as the initial manifestation of small and medium-sized vasculitis: a\u00a0retrospective study. Rheumatol Int 40:1667\u20131674. https:\/\/doi.org\/10.1007\/s00296-020-04652-y","journal-title":"Rheumatol Int"},{"key":"1725_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/keu370","volume":"54","author":"M Andr\u00e9s","year":"2015","unstructured":"Andr\u00e9s\u00a0M, Sivera\u00a0F, Alonso\u00a0S, Pack\u00a0C (2015) MRI myositis sine myositis: the importance of the histopathology. Rheumatol 54:76. https:\/\/doi.org\/10.1093\/rheumatology\/keu370 (United Kingdom)","journal-title":"Rheumatol"},{"key":"1725_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1759720X14566617","volume":"7","author":"F Blaes","year":"2015","unstructured":"Blaes\u00a0F (2015) Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis 7:45\u201355. https:\/\/doi.org\/10.1177\/1759720X14566617","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1725_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae038","author":"MP Collins","year":"2024","unstructured":"Collins\u00a0MP, Hadden\u00a0RDM, Luqmani\u00a0RA (2024) Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: a\u00a0survey of 312 patients. Baillieres Clin Rheumatol. https:\/\/doi.org\/10.1093\/rheumatology\/keae038","journal-title":"Baillieres Clin Rheumatol"},{"key":"1725_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2023","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH et\u00a0al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83:30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"1725_CR31","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1093\/rheumatology\/keaa079","volume":"59","author":"M Krusche","year":"2020","unstructured":"Krusche\u00a0M, Ruffer\u00a0N, Schneider\u00a0U et\u00a0al (2020) Tocilizumab treatment for polyarteritis nodosa. Rheumatol 59:E63\u2013E65. https:\/\/doi.org\/10.1093\/rheumatology\/keaa079 (United Kingdom)","journal-title":"Rheumatol"},{"key":"1725_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/rheumatology\/keac332","volume":"62","author":"J Hadjadj","year":"2023","unstructured":"Hadjadj\u00a0J, Canzian\u00a0A, Karadag\u00a0O et\u00a0al (2023) Use of biologics to treat relapsing and\/or refractory polyarteritis nodosa: data from a\u00a0European collaborative study. Rheumatol 62:341\u2013346. https:\/\/doi.org\/10.1093\/rheumatology\/keac332","journal-title":"Rheumatol"},{"key":"1725_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mus.24207","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner\u00a0A, Barnett\u00a0C, Bril\u00a0V (2014) INCAT disability score: A\u00a0critical analysis of its measurement properties. Muscle Nerve 50:164\u2013169. https:\/\/doi.org\/10.1002\/mus.24207","journal-title":"Muscle Nerve"},{"key":"1725_CR34","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol\u00a0L, Crabtree\u00a0M, Herepath\u00a0M et\u00a0al (2021) Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J\u00a0Neurol 268:3706\u20133716. https:\/\/doi.org\/10.1007\/s00415-020-09998-8","journal-title":"J Neurol"},{"key":"1725_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00115-022-01377-0","volume":"94","author":"AL Fisse","year":"2023","unstructured":"Fisse\u00a0AL, Motte\u00a0J, Gr\u00fcter\u00a0T et\u00a0al (2023) Public health situation of CIDP patients in nine German centers\u2014neuritis network Germany. Nervenarzt 94:320\u2013326. https:\/\/doi.org\/10.1007\/s00115-022-01377-0","journal-title":"Nervenarzt"},{"key":"1725_CR36","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00415-016-8100-9","volume":"263","author":"A Grimm","year":"2016","unstructured":"Grimm\u00a0A, Vittore\u00a0D, Schubert\u00a0V et\u00a0al (2016) Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP. J\u00a0Neurol 263:1074\u20131082. https:\/\/doi.org\/10.1007\/s00415-016-8100-9","journal-title":"J Neurol"},{"key":"1725_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/ene.15156","volume":"29","author":"T Gr\u00fcter","year":"2022","unstructured":"Gr\u00fcter\u00a0T, Motte\u00a0J, Bulut\u00a0Y et\u00a0al (2022) Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A\u00a0prospective cohort study of different CIDP subtypes and disease stages. Eur J Neurol 29:583\u2013592. https:\/\/doi.org\/10.1111\/ene.15156","journal-title":"Eur J Neurol"},{"key":"1725_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh\u00a0PYK, van Doorn\u00a0PA, Hadden\u00a0RDM et\u00a0al (2021) European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a\u00a0joint Task Force\u2014Second revision. J\u00a0Peripher Nerv Syst 26:242\u2013268. https:\/\/doi.org\/10.1111\/jns.12455","journal-title":"J Peripher Nerv Syst"},{"key":"1725_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11910-023-01264-4","volume":"23","author":"P Gupta","year":"2023","unstructured":"Gupta\u00a0P, Mirman\u00a0I, Shahar\u00a0S, Dubey\u00a0D (2023) Growing Spectrum of Autoimmune Nodopathies. Curr Neurol Neurosci Rep 23:201\u2013212. https:\/\/doi.org\/10.1007\/s11910-023-01264-4","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1725_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/a-1134-5345","volume":"39","author":"S Gingele","year":"2020","unstructured":"Gingele\u00a0S, Seeliger\u00a0T, Skripuletz\u00a0T (2020) Therapien bei der chronisch inflammatorischen demyelinisierenden Polyneuropathie. Nervenheilkunde 39:397\u2013403. https:\/\/doi.org\/10.1055\/a-1134-5345","journal-title":"Nervenheilkunde"},{"key":"1725_CR41","doi-asserted-by":"crossref","unstructured":"Dyck\u00a0PJ, Brien\u00a0PO, Swanson\u00a0C, et al (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1173\u20131176","DOI":"10.1212\/WNL.35.8.1173"},{"key":"1725_CR42","doi-asserted-by":"publisher","unstructured":"Matsuda\u00a0M, Hoshi\u00a0K, Gono\u00a0T, et al (2004) Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 224:29\u201335. https:\/\/doi.org\/10.1016\/j.jns.2004.05.014","DOI":"10.1016\/j.jns.2004.05.014"},{"key":"1725_CR43","doi-asserted-by":"publisher","unstructured":"M\u00fcnch\u00a0C, Anagnostou\u00a0P, Meyer\u00a0R, Haas\u00a0J (2007) Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 256:100\u2013102. https:\/\/doi.org\/10.1016\/j.jns.2007.02.027","DOI":"10.1016\/j.jns.2007.02.027"},{"key":"1725_CR44","doi-asserted-by":"publisher","unstructured":"Gorson\u00a0KC, Natarajan\u00a0N, Ropper\u00a0AH, Weinstein\u00a0R (2007) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle and Nerve 35:66\u201369. https:\/\/doi.org\/10.1002\/mus.20664","DOI":"10.1002\/mus.20664"},{"key":"1725_CR45","doi-asserted-by":"publisher","unstructured":"Gr\u00fcter\u00a0T, Mohamada\u00a0N, Rilkea\u00a0N et al (2023) Propionate exerts neuroprotective and neuroregenerative effects in the peripheral nervous system. PNAS 120: https:\/\/doi.org\/10.1073\/pnas.2216941120","DOI":"10.1073\/pnas.2216941120"},{"key":"1725_CR46","doi-asserted-by":"publisher","unstructured":"Good\u00a0JL, Chehrenama\u00a0M, Mayer\u00a0RF, Lee Koski\u00a0C (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51:1735\u20131738. https:\/\/doi.org\/10.1212\/WNL.51.6.1735","DOI":"10.1212\/WNL.51.6.1735"},{"key":"1725_CR47","doi-asserted-by":"crossref","unstructured":"Mahdi-Rogers\u00a0M, Kazmi\u00a0M, Ferner\u00a0R et al (2009) Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 118\u2013124","DOI":"10.1111\/j.1529-8027.2009.00221.x"},{"key":"1725_CR48","doi-asserted-by":"publisher","unstructured":"Press\u00a0R, Askmark\u00a0H, Svenningsson\u00a0A et al (2014) Autologous haematopoietic stem cell transplantation: A viable treatment option for CIDP. J Neurol Neurosurg Psychiatry 85:618\u2013624. https:\/\/doi.org\/10.1136\/jnnp-2013-306014","DOI":"10.1136\/jnnp-2013-306014"},{"key":"1725_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/jns.12118","volume":"20","author":"EK Vanhoutte","year":"2015","unstructured":"Vanhoutte\u00a0EK, Draak\u00a0THP, Gorson\u00a0KC et\u00a0al (2015) Impairment measures versus inflammatory RODS in GBS and CIDP: A\u00a0responsiveness comparison. J\u00a0Peripher Nerv Syst 20:289\u2013295. https:\/\/doi.org\/10.1111\/jns.12118","journal-title":"J Peripher Nerv Syst"},{"key":"1725_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells12202456","author":"M Oeztuerk","year":"2023","unstructured":"Oeztuerk\u00a0M, Henes\u00a0A, Schroeter\u00a0CB et\u00a0al (2023) Current Biomarker Strategies in Autoimmune Neuromuscular Diseases. Cells. https:\/\/doi.org\/10.3390\/cells12202456","journal-title":"Cells"},{"key":"1725_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ene.16023","volume":"31","author":"PL Poser","year":"2024","unstructured":"Poser\u00a0PL, Sajid\u00a0GS, Beyer\u00a0L et\u00a0al (2024) Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 31:1\u20139. https:\/\/doi.org\/10.1111\/ene.16023","journal-title":"Eur J Neurol"},{"key":"1725_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.723009","volume":"12","author":"F Stascheit","year":"2021","unstructured":"Stascheit\u00a0F, Hotter\u00a0B, Klose\u00a0S et\u00a0al (2021) Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants\u2014A Potential Novel Biomarker of Disease Activity. Front Neurol 12:1\u20139. https:\/\/doi.org\/10.3389\/fneur.2021.723009","journal-title":"Front Neurol"},{"key":"1725_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","volume":"24","author":"GGA van Lieverloo","year":"2019","unstructured":"van Lieverloo\u00a0GGA, Wieske\u00a0L, Verhamme\u00a0C et\u00a0al (2019) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J\u00a0Peripher Nerv Syst 24:187\u2013194. https:\/\/doi.org\/10.1111\/jns.12319","journal-title":"J Peripher Nerv Syst"},{"key":"1725_CR54","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1093\/brain\/awad234","volume":"146","author":"S Keddie","year":"2023","unstructured":"Keddie\u00a0S, Smyth\u00a0D, Keh\u00a0RYS et\u00a0al (2023) Peripherin is a\u00a0biomarker of axonal damage in peripheral nervous system disease. Brain 146:4562\u20134573. https:\/\/doi.org\/10.1093\/brain\/awad234","journal-title":"Brain"},{"key":"1725_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332398","author":"L Wieske","year":"2023","unstructured":"Wieske\u00a0L, Michael\u00a0MR, In\u2019T Veld\u00a0SGJG et\u00a0al (2023) Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy. J\u00a0Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2023-332398","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1725_CR56","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/acn3.331","volume":"3","author":"I Quast","year":"2016","unstructured":"Quast\u00a0I, Keller\u00a0CW, Hiepe\u00a0F et\u00a0al (2016) Terminal complement activation is increased and associated with disease severity in CIDP. Ann Clin Transl Neurol 3:730\u2013735. https:\/\/doi.org\/10.1002\/acn3.331","journal-title":"Ann Clin Transl Neurol"},{"key":"1725_CR57","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann\u00a0H, Hoffmann\u00a0S, Ruck\u00a0T et\u00a0al (2023) Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A\u00a010-Year Real-World Data Analysis of German Claims Data. Neuroepidemiology 57:121\u2013128. https:\/\/doi.org\/10.1159\/000529583","journal-title":"Neuroepidemiology"},{"key":"1725_CR58","volume-title":"Myasthenia gravis\u2014Pathophysiology, diagnosis, and treatment","author":"MR Tannemaat","year":"2024","unstructured":"Tannemaat\u00a0MR, Huijbers\u00a0MG, Verschuuren\u00a0JJGM (2024) Myasthenia gravis\u2014Pathophysiology, diagnosis, and treatment, 1.\u00a0Aufl. Elsevier, B.V","edition":"1"},{"key":"1725_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/nejmoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe\u00a0GI, Kaminski\u00a0HJ, Aban\u00a0IB et\u00a0al (2016) Randomized Trial of Thymectomy in Myasthenia Gravis. N\u00a0Engl J Med 375:511\u2013522. https:\/\/doi.org\/10.1056\/nejmoa1602489","journal-title":"N Engl J Med"},{"key":"1725_CR60","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir\u00a0MK, Hobson-Webb\u00a0LD, Benatar\u00a0M et\u00a0al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"1725_CR61","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl\u00a0F, Eriksson-Dufva\u00a0A, Budzianowska\u00a0A et\u00a0al (2022) Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"1725_CR62","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H Wiendl","year":"2022","unstructured":"Wiendl\u00a0H, Meisel\u00a0A (2022) Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie, 2022, DGN. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. AWMF online,"},{"key":"1725_CR63","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite\u00a0MI, Jacob\u00a0S, Viegas\u00a0S et\u00a0al (2008) IgG\u00a01 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis. Brain 131:1940\u20131952. https:\/\/doi.org\/10.1093\/brain\/awn092","journal-title":"Brain"},{"key":"1725_CR64","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1212\/wnl.29.5.654","volume":"29","author":"M Tsujihata","year":"1979","unstructured":"Tsujihata\u00a0M, Hazama\u00a0R, Ishii\u00a0N et\u00a0al (1979) Limb muscle endplates in ocular myasthenia gravis: Quantitative ultrastructural study. Neurology 29:654\u2013661. https:\/\/doi.org\/10.1212\/wnl.29.5.654","journal-title":"Neurology"},{"key":"1725_CR65","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","volume":"139","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann\u00a0S, Harms\u00a0L, Schuelke\u00a0M et\u00a0al (2020) Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol 139:1119\u20131122. https:\/\/doi.org\/10.1007\/s00401-020-02147-5","journal-title":"Acta Neuropathol"}],"updated-by":[{"DOI":"10.1007\/s00115-024-01761-y","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000}}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01725-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T07:03:22Z","timestamp":1731740602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01725-2","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s00115-024-01761-y","asserted-by":"object"}]},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"4 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Es wurden Abb. verwechselt und falsch beschriftet.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00115-024-01761-y","URL":"https:\/\/doi.org\/10.1007\/s00115-024-01761-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Hoffmann, M.-T.\u00a0Holzer, C.\u00a0Preu\u00dfe, T.\u00a0Ruck, N.\u00a0Ruffer, F.\u00a0Stascheit und W.\u00a0Stenzel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}